Cytokinetics, Inc. (CYTK) Posts Q1 Loss of 27c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cytokinetics' (CYTK) Q1 Results Solid, BENEFIT Remains in Focus - Roth
May 7, 2014 9:29 AM EDTRoth Capital has Cytokinetics (Nasdaq: CYTK) at Buy with a target price of $13 following Q1 results.
After markets closed Tuesday, Cytokinetics reported Q1 EPS of ($0.27), $0.07 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $8 million versus the consensus estimate of $7.69 million.
Analyst Joseph Pnatginis noted that Cytokinetics is now prepping for the potential next steps for tirasemtiv... More
Cytokinetics (CYTK) a Buy on Partnered Pipeline, Needham & Company Says
May 7, 2014 8:41 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $15 price target on Cytokinetics (NASDAQ: CYTK) following Q1 results.
Messer comments, "Cytokinetics ended 1Q:14 with $101.9 million in cash, which we estimate is sufficient to fund the company at least through 2015. On its earnings... More
